Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Magro

Showing results (291-300 of 341) with videos related to

Pageof 35
Sort By:
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Therapeutic Advances in Gastroenterology|September 22, 2017
Clinical performance of an infliximab rapid quantification assayFernando Magro, Joana Afonso, Susana Lopes, et al.
Nature Reviews. Gastroenterology & Hepatology|April 22, 2025
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health responseVirginia Solitano, Charles N Bernstein, Iris Dotan, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 YearsFernando Magro, Diogo Magalhães, Marta Patita, et al.
Autoimmunity Reviews|December 21, 2023
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness studyVirginia Solitano, Paola Facheris, Magnus Petersen, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Journal of Crohn'S & Colitis|June 21, 2011
Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom studyJohan Burisch, Silvija Cukovic-Cavka, Ioannis Kaimakliotis, et al.
Ebiomedicine|June 21, 2017
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic EscalationFernando Magro, Joana Afonso, Susana Lopes, et al.
United European Gastroenterology Journal|June 15, 2023
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective studyFernando Magro, Maria Manuela Estevinho, Gaia Catalano, et al.
Pageof 35

Showing results (291-300 of 341) with videos related to

Sort By:
Pageof 35
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Therapeutic Advances in Gastroenterology|September 22, 2017
Clinical performance of an infliximab rapid quantification assayFernando Magro, Joana Afonso, Susana Lopes, et al.
Nature Reviews. Gastroenterology & Hepatology|April 22, 2025
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health responseVirginia Solitano, Charles N Bernstein, Iris Dotan, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 YearsFernando Magro, Diogo Magalhães, Marta Patita, et al.
Autoimmunity Reviews|December 21, 2023
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness studyVirginia Solitano, Paola Facheris, Magnus Petersen, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Journal of Crohn'S & Colitis|June 21, 2011
Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom studyJohan Burisch, Silvija Cukovic-Cavka, Ioannis Kaimakliotis, et al.
Ebiomedicine|June 21, 2017
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic EscalationFernando Magro, Joana Afonso, Susana Lopes, et al.
United European Gastroenterology Journal|June 15, 2023
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective studyFernando Magro, Maria Manuela Estevinho, Gaia Catalano, et al.
Pageof 35